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1. Introduction
Alzheimer’s disease has a well-de¢ned neuropatho-
logic pro¢le which includes a surfeit of extracellular
amyloid deposits (comprised mainly of the AL pep-
tide derived by endoproteolysis of the L-amyloid pre-
cursor protein (APP)), accretion of intracellular neu-
ro¢brillary tangles (NFTs), comprised mainly of
hyperphosphorylated forms of the microtubule-asso-
ciated protein tau (d), reduced synaptic density, and
loss of cholinergic neurons of the basal forebrain
(reviewed in [1]). The disease clearly has a complex
etiology, existing in early- and late-onset familial
forms (‘FAD’, familial Alzheimer’s disease) in addi-
tion to manifestation in a common sporadic (idio-
pathic) form. Linkage and positional cloning strat-
egies exploiting FAD kindreds have so far de¢ned
three genes associated with FAD, the substrates for
transgenic modelling of AD. These are APP on chro-
mosome 21 [2], presenilin 1 (PS1) on chromosome 14
[3] and presenilin 2 (PS2) on chromosome 1 [4,5]. A
fourth FAD locus is believed to be located on chro-
mosome 12, with the alpha 2 macroglobulin gene
being a locus under consideration [6]. The O4 allele
of the apoE gene [7], a modi¢er associated with late-
onset AD, is located on chromosome 19. Together,
these observations have been taken to indicate both
environmental and genetic risk factors triggering a
chain of events which converge at a ¢nal pathogenic
pathway leading to the stereotypic neuropathology
[8].
The relative importance of amyloid deposition and
tangle formation in AD pathogenesis have been in-
tensely debated, with proponents of two camps
dubbed as ‘baptists’ and ‘tauists’, respectively. Muta-
tions in the APP gene in FAD kindreds, early accu-
mulation of amyloid deposits in Down’s syndrome
patients (where the APP gene is triplicated) prior to
the onset of frank dementia [9], and toxic e¡ects of
AL in cell culture paradigms [10] comprised early
data in favor of the baptists. Additionally, the in-
creased level of AL during normal aging is correlated
with cognitive deterioration in rodents (rats [11],
mice [12^15]), non-human primates [16,17], and hu-
mans [18,19]. Conversely, tauists have cited poor cor-
relations between amyloid burden and cognitive de-
cline in the elderly and a good correlation with tangle
formation [20]. As described below, recent biochem-
ical and genetic studies have continued to provide
evidence in favor of AL peptide as a key player in
AD pathogenesis, with the corollary that transgenic
approaches to AD have been highly skewed towards
APP and interacting genes (i.e. presenilins). On the
other hand, the concept of an important pathological
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role for neuro¢brillary tangles has received impetus
from the description of tau gene mutations linked to
the development of frontotemporal dementia [21].
Augmentation of the current arsenal of transgenic
animals with new lines expressing human tau pro-
teins is thus eagerly awaited.
2. Objectives
In this review we ¢rst provide an overview of the
transgenic mice proposed to recapitulate facets of the
AD clinical phenotype, with a brief description of
molecular parameters and behavioral performance.
Many such lines have now been created and to strat-
ify these AD models, we base our discussions upon
¢ve expectations listed below (although some of these
might seem so self-evident as to be prosaic, in fact
most research conducted thus far falls short of these
notional guidelines). Our proposed expectations for a
credible model of AD are:
1. Mice should exhibit progressive neuropathology
culminating in at least one, and preferably more,
of the accepted pathologic hallmarks of AD (pla-
ques, tangles, loss of cholinergic neurons).
2. Mice should exhibit cognitive de¢cits as well as
neuropathologic changes noted in 1. Such cogni-
tive changes should be robust, and evident in dif-
ferent behavioral paradigms targeting the same
memory system. Ideally, behavioral paradigms
employed to test mice should address neuroana-
tomic structures that are a¡ected in AD (e.g. the
hippocampus).
3. In the case of experiments employing FAD muta-
tions, phenotypic changes documented in 2 and 3
should be correlated with the presence of the FAD
mutations, and should be absent or less overt in
age-matched mice expressing wt gene alleles ex-
pressed at equal (or greater) steady-state levels.
(This is not to exclude the possibility that, using
the precedent of APP gene triplication in Down’s
syndrome, overexpression of wt APP might also
be enlightening as to AD pathogenic pathways.)
4. Key facets of the phenotype as per 1^3 should be
con¢rmed in independent Tg lines harboring the
same construct, to exclude the contribution of in-
sertional mutations. For example, recessive alleles
in the case of mice homozygosed for the transgene
array, or haploinsu⁄ciency due to inadvertent dis-
ruption of a gene a¡ecting neurophysiology in the
case of hemizygous Tg arrays.
5. Key facets of the phenotype as per 1^3 should
have been con¢rmed in several laboratories [22].
Since cognitive changes are so central to AD, the
second part of the review addresses in somewhat
greater depth behavioral paradigms used to assess
Tg mice, with a discussion of the Tg mice that
come closest to ful¢lling criteria 1 and 3^5. Bearing
in mind di⁄culties that have been encountered even
replicating the same experiments in di¡erent labora-
tories [22], the operational complexities and subtle-
ties associated with achieving goal 5 present a formi-
dable challenge to AD researchers. In the third
section we discuss the increasing use of electrophysi-
ology as an adjunct technique to assess synaptic plas-
ticity of Tg AD mice. Lastly, we speculate as to
technological improvements and intellectual advan-
ces that might place us nearer to the intended goal
of a robust animal model for AD.
3. Current transgenic models of AD
3.1. APP transgenic mice
APP is a type I transmembrane protein expressed
in a number of tissues. Endoproteolysis sites to gen-
erate AL (which comes in at least two forms called
AL1ÿ40 and AL1ÿ42) as well as other metabolites are
documented elsewhere in this volume (see chapters
by Gandy and Selkoe). Di¡erent mutations are asso-
ciated with di¡erent patterns of amyloid peptide ac-
cumulation. Thus the ‘Swedish’ mutation K670N/
M671L is associated with overproduction of AL via
stimulation of the L-secretase pathway and this cul-
minates in a predominance of AL1ÿ40 [23]. Con-
versely, the V717F and V717I mutations appear to
enhance Q-secretase-mediated cleavage resulting in a
predominance of AL1ÿ42 [24].
Viewed, perhaps unfairly, from the side-lines of
prion biology, the path of APP transgenesis has ap-
peared fraught with problems. Early Tg mice failed
to develop convincing AD-related pathology and
were even used in one instance as negative controls
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for a neurologic syndrome in prion protein Tg mice
[25]. Some of the problems with APP mice proved to
be trivial in nature, to do either with the use of in-
appropriate vectors with poor expression levels, or
inadequate knowledge of performing neuropatholog-
ical studies in mice, lack of aged controls, while a
more notorious incident involved creative manipula-
tion of pathological specimens. In any event, the ¢eld
moved on and as of the mid 1990s a number of
‘second generation’ Tg lines were created which suc-
cessfully expressed high levels of APP and/or its cru-
cial metabolite, the AL peptide (Table 1). At this
juncture more subtle problems and puzzles emerged.
In this section our main focus is second generation
mice which go on to develop amyloid plaques, with a
brief discussion of associated paradoxes and un-
knowns. The reader is also directed to excellent re-
views which chronicle the complete history of APP
transgenesis [26,27].
3.1.1. PDAPP mice
Human APP exhibits a number of splice variants
of 695, 751 and 775 amino acid residues, re£ecting
the presence or absence of exons 7 and 8 encompass-
ing the so-called Kunitz inhibitor domain. These
mice, described by Games and co-workers [28],
were cleverly constructed so as to encompass all of
these spliced forms. They contain an APP cDNA
interposed with a genomic DNA fragment encom-
passing introns 6^8, and driven by the platelet-de-
rived growth factor L-chain (PDGFL) promoter,
hence the PDAPP nomenclature. The APP cDNA
encompasses the ‘Indiana’ mutation, V717F, which
is associated with enhanced cleavage at the Q-secre-
tase site to generate a preponderance of AL1ÿ42 [29].
These mice exhibit £orid amyloid deposition com-
mencing at ca. 6^9 months. Neuroanatomic distribu-
tion of the plaques, whose major component is
AL1ÿ42, is detailed in Table 2. Very detailed neuro-
pathological analysis has de¢ned thio£avin-S positive
AL deposits, neuritic plaques, synaptic loss, astrocy-
tosis, and microgliosis. Overt NFTs were absent, as
they are for other APP mice, though hyperphos-
phorylated forms of tau are detectable. Neuronal
loss was not evident [30]. Unlike some APP overex-
presser mice described below, premature death is not
reported to be associated with this Tg line (as main-
tained in an outbred Swiss-WebsterUC57B6/DBA
genetic background), nor does it become apparent
in crosses to the C57BL6 background [31].
3.1.2. PrP promoter APP Tg mice (Tg2576) and
their forebears
The prion protein gene has been used to great
e¡ect in AD transgenesis, and was ¢rst described
by Hsiao, Borchelt, Carlson and co-workers. Exploit-
ing the position-independent, pan-neuronal expres-
sion of a prion protein (PrP) gene-derived vector
Table 1
Genetic parameters of TgAPP mice with amyloid deposits
Tg line APP cDNA Mutation Transgene
promoter
Strain background APP over-
expression
PDAPP, South San Francisco [28,31] 695+751+770
(see text)
V717F PDGF-L Swiss Webster,
C57BL6, DBA/2
10U
Tg2576, Minnesota [36,37] 695 Swedish Hamster PrP C57BL6USJL 5^6U
TgAPP22, Basel [39] 751 with optimized
Kozak sequence
Swedish plus
V717F
Human Thy-1 C57 2U
TgAPP23, Basel [39] 751 with optimized
Kozak sequence
Swedish Murine Thy-1 C57 7U
TgAPP/Ld/2, Leuven [40] 695 V717I Murine Thy-1 FVB/N and
FVB/NUC57BL6
25U (RNA)
TgAPP/Sw/1, Leuven [40] 695 Swedish Murine Thy-1 FVB/N 7U (RNA)
Tg2576 plus mutant presenilin 1 [54] 695 Swedish Hamster PrP C57BL6USJL 5^6U
(protein)
Tg Hu/MoAPP plus presenilin 1 [55] 695 (mouse/human
hybrid)
Swedish Mouse PrP
[111]
C57BL6J plus
C3H/HeJ mixture
V2U
(protein)
APP overexpression refers to protein unless noted otherwise.
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dubbed cos.Tet [32], these workers described mice
expressing mutant and wt APP695 DNAs such that
net levels of APP often transcended those seen in
non-Tg mice (up to 3.6U the level of mouse APP
expression in the initial series of mice) [33]. These
mice, created in the FVB/N inbred strain background
exhibited a heightened frequency of spontaneous
death accompanied by behavioral changes. These in-
clude neophobia, which was progressive with age
from about 1 to 3 months, depending upon the Tg
line however, and impaired spontaneous alternation
in the Y-maze. The latter impairment usually pre-
ceded neophobia, but was often paralleled by slow-
ness, thigmotaxis, and other neurologic behavioral
signs (see the following section for a more detailed
discussion of these behavioral phenomena). How-
ever, no overt AD-like pathology was evident, nor
were the observed changes more noticeable in mice
carrying FAD mutations than those expressing wt
APP, suggesting that this syndrome was most likely
a re£ection of APP overexpression rather than crea-
tion of a facet of an AD pathogenic pathway. The
precise cause of premature death in APP (FVB/N)
mice was not evident from routine autopsy though
subsequent work showed that the percentage animals
a¡ected could be markedly modulated, and in some
cases prevented, by crosses to di¡erent inbred lines
[34]. In crosses to introduce other transgenes, wt
superoxide dismutase (SODl) was protective whereas
basic ¢broblast growth factor (FGF2), which is neu-
roprotective in some settings, heightened the lethal
e¡ects of APP expression. More recently, changes
Table 2
Neuropathology in APP Tg mice
Tg linea Age at onset of
amyloid
deposition
Plaque
morphology
Plaque
location
Astro-
cytosis
Micro-
gliosis
Neuronal
loss
NFT
elements?
Refer-
ences
PDAPP from
6 months
onwards
di¡use and
compacted
plaques
hippo-
campus,
Corp Call,
CC
yes yes not signi¢cant
at 18 months
AT8 positive [28,30,
31]
Tg2576 at 9^12
months
deposits stain
with Congo
Red
hippo-
campus, CC,
amygdala
yes yes none at 16
months
AT8 positive [36,38,
112]
Tg2576 plus
mutant PS1
6 months as above as above yes yes N.D. (as above) [54]
TgAPP22 18 months mostly di¡use hippo-
campus
yes yes N.D. AT8 staining around
Congo Red staining
plaques, no NFTs
[39]
TgAPP23 6 months congophilic
and di¡use
hippo-
campus,
neocortex
yes yes up to 25% in
CA1 at 14^18
months
as above [39,113]
TgAPP/Ld/2 13^18 months di¡use,
composed in
major part of
AL1ÿ42
hippo-
campus, CC
yes yes no overt
neuronal loss
or degeneration
AT8 staining [40]
TgAPP/Sw/1 18^25 months di¡use,
composed in
major part of
AL1ÿ40
hippo-
campus, CC
yes yes as above AT8 staining [40]
Tg Hu/MoAPP
plus PS1
10 months plaques
composed of
both AL1ÿ40
and AL1ÿ42
hippo-
campus, CC
yes yes N.D. N.D. [55]
N.D., not done; CC, cerebral cortex.
aSee Table 1.
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in cerebral microcirculation have been noted in
Tg1130H and Tg6209 APP transgenic mice. Notably,
these changes were also nulli¢ed by the presence of
wt SOD1, introduced either as a transgene or topi-
cally [35].
Microinjection of cos.Tet/APP constructs into
oocytes of a di¡erent genetic background,
(C57BL6JUSJL F2) allowed the Tg2576 line to be
established. The expression level of 5.6 þ 0.3Uendog-
enous APP surpassed those of earlier generation PrP
mice. Very notably, these mice do go on to develop
amyloid plaques, with this pathologic ¢nding pre¢g-
ured by behavioral alterations [36]. Reductions in
long-term potentiation in hippocampal neurons in
tissue slices or in vivo are concurrent with or follow
amyloid deposition [37], though insu⁄cient time
points were sampled to make any ¢rm conclusions
about causality [26]. Other analyses and crosses with
these animals further underscore the complex rela-
tionship between amyloid synthesis, behavioral
changes, and lethality (at least as measured in
mice). When maintained by intercrossing of
C57BL6JUSJL F2 and F3 animals, these mice do
not exhibit high levels of premature death, arguing,
as for the PDAPP mice, that amyloid deposits are
not per se toxic at the organismal level, or, as as-
sessed by light microscopy, at the cellular level [38].
APP-associated lethality does however emerge in
Tg2576 mice as the animals are backcrossed to C57
or FVB/N backgrounds [34].
3.1.3. Thy-1 promoter APP mice
Tg mice were constructed on a C57/D2 back-
ground at Novartis using APP751 cDNAs driven via
the Thy-1 promoter. Like PrP, this promoter also
engenders good levels of transgene expression in
the CNS. The Tg22 line with 2U overexpression,
and encompassing a double-mutant allele (Swedish
plus V717I) developed plaques at 18 months whereas
APP23 mice with higher levels of expression and
carrying the Swedish mutation alone developed pla-
ques considerably earlier, at 6 months. A provocative
¢nding was that the nature of the amyloid deposition
was dependent upon the transgene, presumably re-
£ecting the contributions of the di¡erent APP mu-
tant genotypes, rather than the promoter (mouse vs.
human Thy-1). Amyloid deposits in TgAPP22 mice
were of the di¡use type, whereas those in TgAPP23
mice were compact plaques, positive for Congo Red
birefringence at ¢rst appearance [39].
In other work van Leuven and colleagues also
used the Thy-1 promoter to express mutant and
wild-type APP695 cDNAs, this time in an FVB/N
genetic background [40]. The phenotypic attributes
of these mice ^ premature death, behavioral distur-
bances, amyloid deposition with hyperphosphory-
lated tau ^ echo themes apparent in other mice and
speci¢cally con¢rm earlier observations regarding use
of FVB/N mice (which may be particularly sensitive
to the e¡ects of APP overexpression [33]). Some of
the behavioral traits reported were also present in a
Tg line expressing an APP construct lacking FAD
mutations but ablated for the K-secretase site [41].
These included reduced activity, ‘freezing’ in a novel
environment, increased neophobia, aggressiveness,
and seizures (frequent in FVB/N but rare in
C57BL6 strain background) observed in mice older
than 6 months. These ¢ndings again raise the issue as
to which (if any) of the behavioral traits that have
surfaced in high-level expresser APP mice can be
unequivocally ascribed to the FAD mutations them-
selves [40] (see also Section 2).
3.1.4. NSE/APP mice and mice expressing arti¢cial
fragments of APP
Several groups have created mice expressing wt
APP751 cDNAs under the control of the neuron-spe-
ci¢c enolase promoter. Generally, expression levels
are lower than with other promoters [42], reiterating
the experience with NSE-driven transgenic expres-
sion of the prion protein. It is of some interest that
some of these mice exhibit age-dependent de¢cits in
spatial learning ^ progressive (from 6^12 months) for
spontaneous alternation in the Y-maze and probe
trials of the water maze, but not in the acquisition
phase, which was equally impaired at both ages [43]
^ however, a detailed critique highlights some ambi-
guities related to protein expression levels, the nature
of extracellular deposits, and comparisons to related
mice on di¡erent strain backgrounds [27].
Besides conventional cDNAs encoding full-length
forms of APP, some studies have utilized truncated
forms of APP. Here the possibility of side-stepping
the problems associated with high-level expression of
APP (e.g. premature death and confounding behav-
ioral abnormalities) has to be balanced against the
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possibility of producing molecules that are metabo-
lized or expressed in ways that di¡er from the phys-
iological expression of APP in the secretory pathway.
Two well-known studies fall within this category. In
the ¢rst, LaFerla and colleagues expressed AL pep-
tide minus a signal peptide such that it was synthe-
sized in the cytoplasm [44]. The mice exhibited re-
duced lifespan and apoptotic degeneration of CNS
neurons but no AD-related pathology, presumably
because AL does not normally accumulate in this
cellular compartment. In the second, Nalbantoglu
and co-workers expressed a 99 residue sequence cor-
responding to the C-terminus of wt human APP.
Provocatively, the mice displayed de¢cits in spatial
learning acquisition (tested at 8 months only) accom-
panied by thigmotaxic behavior in early training tri-
als, and reduction in long-term potentiation, thereby
o¡ering a potential parallel to the widely studied
Tg2576 mice. On the other hand, tinctorially de¢ned
amyloid deposits and evidence for progression in
cognitive and electrophysiological perturbations
have yet to be described for these animals.
3.2. APP double transgenic mice
3.2.1. APP/presenilin Tg mice
Presenilins are polytopic membrane proteins asso-
ciated with intracellular high molecular weight pro-
tein complexes. Since their ¢rst sighting in mutant
form in FAD kindreds, a wealth of evidence derived
from transfected cells has accumulated in favor of
the notion that these molecules a¡ect the Q-secretases
that endoproteolyse APP. FAD presenilin mutations
are usually missense substitutions which appear to be
dominant gain-of-function alleles, since the pheno-
type of PS gene ablation in mice bears little resem-
blance to AD [45,46], and since no putative null al-
leles have been identi¢ed in FAD kindreds. An
ongoing debate concerns whether there is a direct
physical interaction between presenilins and Q-secre-
tases, whether the e¡ect is indirect via an impact of
presenilins upon protein tra⁄cking [47], or whether
presenilins actually are Q-secretases [48]. Irrespective
of these mechanistic questions, for the purposes of
our discussion it is su⁄cient to note that the e¡ect
upon APP processing is robust, and also operates in
transgenic mice.
Several groups have established that young mice
expressing presenilin 1 under the control of the PrP
or PDGF-L promoter, or presenilin 2 under the con-
trol of the chicken L-actin promoter exhibit potent
elevation of brain AL levels [49^52]. The phenomen-
on is also present in presenilin knock-out mice,
(which normally exhibit skeletal abnormalities) res-
cued by a trans-acting mutant PS1 transgene [53].
This indicates that presenilin FAD mutations are
gain-of-function lesions that do not grossly impair
wt. activities.
In accord with the elevated steady-state levels of
AL evident in young TgAPPUTgPS1 double Tg
mice, aged animals of the same genotype exhibit ac-
celeration in the rate of amyloid plaque deposition
compared to their Tg APP littermates [54,55]. Insofar
as deposition of bona ¢de amyloid plaques seems
dependent upon exceeding a threshold in AL produc-
tion rate, presenilin genes are an invaluable tool in
routinely achieving this important hallmark of
pathogenesis. On the other hand, it must be born
in mind that extant PS1/APP Tg mice still fail to
exhibit other hallmarks of AD, namely NFTs and
cell loss.
3.2.2. TgAPPUAD modi¢er transgenes
There is an extensive literature to the e¡ect that
in£ammatory changes play an important role in AD
pathogenesis [56,57], with some data speci¢cally ¢n-
gering an involvement of transforming growth factor
TGF-1 [58]. Exploiting the PDAPP Tg line, expres-
sion of TGF-L1 under the control of the glial ¢bril-
lary acidic protein promoter resulted in an increased
deposition of AL peptide within plaques, with an
emphasis upon cerebrovascular and meningeal depo-
sition, which is not usually prominent in PDAPP
mice [59]. Another potential AD modi¢er is ApoE,
where homozygosity for the O4 allele is strongly im-
plicated as a risk factor for late-onset AD [60,61], as
well as by potential e¡ects of ApoE protein upon
amyloid deposition [62]. Bales and co-workers have
reported that an ApoE null genotype dramatically
reduces amyloid deposition PDAPP mice [63], con-
sistent with this notion. However, in more recent
studies transgenic expression of the ‘pro-AD’ O4 al-
lele (and also O3), attenuated rather than enhanced
amyloid deposition in TgAPPV717F mice prone to
amyloid deposition [64]. In addition to further ex-
periments to sort out this discrepancy we can envis-
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age that genome scans for loci which modulate the
phenotypes in extant Tg mice will yield a fresh crop
of putative AD modi¢er genes.
4. Behavioral paradigms for testing AD mice
As cognitive changes comprise an early, crucial,
and devastating aspect of AD (which accounts for
about 50^70% cases of dementia [65,66]) some gen-
eral comments on the types of testing paradigms may
be of use. Inevitably, many of the studies to date
have focussed upon changes associated with altered
APP expression/catabolism and besides the Tg mice
enumerated above, models also include rats with ex-
perimental injections of L-APP [67^73]. Since the
hippocampus and the related structures of the ven-
tromedial temporal lobe are a¡ected in the early
stages of Alzheimer’s disease [74,75], tests have fo-
cussed on behaviors like exploration of novel envi-
ronment and spatial learning, known to have neural
representation in the hippocampal region [76^84].
4.1. Behavioral paradigms used
Learning in animals is usually inferred from their
behavior, most often involving locomotor activity.
Therefore cognitive tests must be prefaced with para-
digms examining somatic growth and sensorimotor
development of animals [33,85,86]. The Fox [87] bat-
tery of tests or the testing guidelines outlined by
Crawley and Paylor [88] for assessing sensorimotor
development in mice seem to be most appropriate
here. The plethora of behavioral tests available is
most often represented by the open-¢eld, spontane-
ous alternation, and the Morris water maze tests.
The open-¢eld (OF) test, developed originally by
Hall [89], assesses spontaneous exploratory activity
in a novel environment (e.g. a large, brightly lit are-
na). Thigmotaxic behavior (time spent near the wall),
locomotor activity in the periphery and center and
defecation are good indicators of within-session ha-
bituation and/or neophobia (fear of novel environ-
ment characterized by cessation in exploratory activ-
ity). A corner index test is a modi¢cation of the
open-¢eld test allowing better quanti¢cation of neo-
phobic behavior. The index represents the number of
times a mouse sni¡s/explores the corners of clean
testing cage during speci¢ed time period. Low scores
of the index, with frequent freezing postures charac-
terize neophobic mice.
Spatial learning is most often assessed through the
spontaneous or forced-choice alternation in a Y- or
T-maze [90] and the place discrimination (PD) ver-
sion of the Morris water maze (WM) test [91]. In
alternation tests, rodent species show a tendency to
alternate their entries to left and right arm of a sym-
metrical Y- or T-maze. The rate of alternation de-
pends on mouse strain [92], maze type [93], age of
subjects [94], and the integrity of the septo-hippo-
campal system [95]. In the place discrimination ver-
sion of the Morris water maze a mouse has to nav-
igate, using extra maze distal spatial cues, to a
submerged (i.e. hidden) platform placed in the
pool. A cued version of the test requires a mouse
to associate the platform position with a visible cue
(e.g. a £ag) located on the platform. Learning of the
association between the cue and platform position
does not depend on a functional hippocampal for-
mation.
4.2. Behavior of APP transgenic mice
Behavioral tests for the mice listed above in Tables
1 and 2 are presented in Table 3. Whenever appro-
priate, we indicate the progressive nature of cognitive
impairment within the tested age range. Behavioral
¢ndings thus far preclude ¢rm conclusions regarding
the role of mutated APP genes in cognitive functions
of the mouse. First, three out of seven types of Tg
mice listed in Tables 1 and 2 were not studied in
behavioral tests (PDAPP, TgAPP22, Tg Hu/
MoAPP). Two other lines (TgAPP/Ld/2 and
TgAPP/Sw/1) were reported to show age-dependant
abnormalities in sensorimotor behavior, like hyper-
activity, anxiety, and later (from 6 months onwards)
seizures [40]. Additionally, these Tg mice showed in-
creased level of neophobia expressed by low corner
index, and increased predisposition to freezing dur-
ing exploration. Such changes in propensity for ex-
ploration could compromise performance in other
learning tests. Although Tg mice were impaired in
the place discrimination, but not in cued version of
the water maze, this impairment was documented in
both mutated TgAPP/Ld/2 and wild-type APP/Wt/4
mice (as compared to their non-Tg controls) within
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age range from 3 to 6 months. These data caution
that the natural tendency to attribute behavioral
problems in mice expressing mutant APP alleles to
the FAD mutations could be erroneous. Since tests
at older ages were not feasible due to high mortality
of these mice [40] it would be informative to see the
tests carried out with ¢ner resolution, at earlier age
points. Only one TgAPP line (Tg2576, [36,37])
showed normal sensorimotor development and ex-
ploration of novel environment when compared to
their non-Tg littermates. When studied in the hippo-
campally dependent learning tests, Tg2576 mice
showed a progressive impairment in spontaneous al-
ternation, and place discrimination spatial learning
Table 3
Behavioral abnormalities of TgAPP mice
Tg linea Sensorimotor development Spontaneous activity Cognitive abnormalities Age progressive
cognitive
abnormality
PDAPP, South San
Francisco [28,31]
not reported not reported not reported not reported
Tg2576, Minnesota
[36,37]
normal sensorimotor
behavior (righting, Preyer,
pupillary re£exes, wire
hanging test) at 16^18
months [37]
normal OF exploration and
emotional response
(defecation rate) to novelty
at 16^18 months [37]
lower Y-maze spontaneous
alternation
yes, from 3 to
10 months
impaired acquisition of
spatial learning in WM,
con¢rmed in the probe trial
yes, from 3 to
10 months
impaired spatial learning
during retest
at 12^15 months
impaired spatial working
memory in forced-choice
T-maze alternation test
yes, from 2 to
10 months
TgAPP22,23 Basel [39] not reported not reported not reported not reported
TgAPP/Ld/2, Leuven
[40]
increased hyperactivity,
anxiety, aggression (from
8 weeks onwards), seizures-
15% of Tg at 6 months or
older (lines not speci¢ed)
increased neophobia,
posture freezing at 3 months
(data not presented)
Impairment in WM spatial
learning acquisition, spatial
bias in probe trial, in both
APP/Ld/2 and APP/Wt/4 as
compared to non-Tg mice
not done
no impairment in visible
platform test, tested at 3^6
months
TgAPP/Sw/1, Leuven
[40]
increased hyperactivity,
anxiety, aggression (from
8 weeks onwards), seizures-
15% of Tg at 6 months or
older (lines not speci¢ed)
increased neophobia (low
corner index data presented),
posture freezing, later than
3 months, (not speci¢ed
exactly)
not reported not done
Tg2576 plus mutant
presenilin 1 [54]
normal sensory and motor
functions (righting and
Preyer re£ex, seizure activity
and coat hanger test)
not reported speci¢cally. impaired Y-maze spontaneous
alternation; scores of APP/
PS1 and APP6PS1 and non-
Tg
increased activity of APP/PS1
(total # of arm entries) vs.
APP = PS1 = non-Tg; all tests
at 3 months
Tg Hu/MoAPP plus
presenilin 1 [55]
not reported not reported not reported not reported
WM, water maze.
aFor detailed characteristics of TgAPP see Table 1 and for their neuropathology see Table 2.
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[36], and more recently in the spatial working mem-
ory measured in forced-choice T-maze alternation
test [37]. Both of the studies on Tg2576 mice dem-
onstrated similar age-dependent deterioration in
spontaneous alternation, spatial learning in the water
maze, and spatial working memory tests. Thus at 2^3
months of age, Tg mice did not di¡er from non-Tg
littermates, while from 10 months onwards learning
performance was inferior. Since the tests address dif-
ferent memory systems (long- and short-term mem-
ory), it would be informative to carry out tests at
ages within 2^10 month range in order to establish
the onset of cognitive impairment in each testing
paradigm. The inclusion of Tg mice expressing
wild-type human APP at levels equal to or greater
than the SweAPP allele would signi¢cantly strength-
en the favored interpretation of progressive neuro-
pathology and cognitive decline associated with the
‘Swedish’ FAD mutation. Finally, while bigenic mice
with increased propensity for amyloid deposition
(from a cross between line Tg2576 and a
TgPS1(M146L) line) also showed impaired spontane-
ous alternation in the Y-maze in the absence of sen-
sorimotor abnormalities [96], no age-dependent pro-
gression of this impairment was reported (all tests
were carried out at 3 months of age).
A second general problem pertaining to TgAPP
mouse models is the use of di¡erent (or hybrid)
strain backgrounds (Table 1). Some transgenic mice
have been developed using derivatives of the 129 [88]
or FVB/N [97] inbred strains. Use of these strains is
based upon a high percentage of successful transgen-
esis but it is unfortunate for behavioral purposes,
since they perform poorly on learning and memory
tasks and may have visual problems due to presence
of the recessive rd (retinal degeneration) allele
[97,98]. Backcrossing parental strains into other
strains more suitable for behavioral testing strains
can circumvent this problem but introduces another,
genetic background variability, a¡ecting behavioral
phenotypes of Tg mice.
In sum, documentation of the behavior of the APP
Tg mice with amyloid deposition is still in its infancy.
Initial studies did not address behavioral changes at
all, while other studies experienced problems of in-
terpretation or confounding e¡ects of strain di¡er-
ences or sensorimotor abnormalities, with the net
result that concerns regarding validity often temper
the conclusions. However, the ¢eld is on a rapid
learning curve and recent studies have used more
rigorous approaches to behavioral design and ad-
dressed the developmental progression of the cogni-
tive impairment [36,37]. Hopefully the detailed on-
togeny of impairment as well as the role of early
experience on later dysfunction will be addressed in
future experimental designs.
5. Cognitive de¢cits and neural function in APP Tg
mice
As well as cognitive changes, it is possible to con-
sider neural function at the cellular and molecular
levels. Changes in synaptic e⁄cacy are thought to
play a key role in the induction and formation of
stable memories in the mammalian brain. Two semi-
nal papers [80,99] described the properties of long-
term potentiation (LTP) in hippocampal slice prepa-
rations as a putative in vitro model for long-term
memory. However, the available experimental evi-
dence cautions against the universal applicability of
this hypothesis [100]. For example, modi¢ed proto-
cols in the water maze paradigm (non-spatial pre-
training) can dissociate the correlation between im-
paired LTP and impaired learning [101^104].
At present, ¢ndings correlating impaired synaptic
plasticity with cognitive de¢cits APP Tg mice are
sparse. Only one mutated Tg line (Tg2576, [37])
showed impairment in LTP (both in vitro and in
vivo), which was also correlated with de¢cits in spa-
tial learning. The amount of variance explained by
this positive relationship was 42% (44% for all mice)
in CA1, and 72% (the same for all mice) for dentate
gyrus regions of the hippocampus. These values
would be slightly smaller if the major axis, a more
appropriate technique for the analysis of relationship
between two recorded variables when both are sub-
ject to experimental error [105], was used instead.
Also, electrophysiological data have yet to be re-
ported in wt Tg APP control lines made using the
PrP promoter. Along the same lines, although anoth-
er mutant TgAPP line (TgAPP/Ld/2) also showed
impaired LTP (compared to non-Tg littermates)
[40], no results were presented for the wild-type
TgAPP/Wt/4 line which showed similar spatial learn-
ing impairments (see objective 3). In fact, some other
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data can be reconciled with the notion of APP-medi-
ated (rather than AL-mediated) e¡ects upon synaptic
plasticity. Impairment in LTP was shown in Tg mice
expressing the C-terminus of wild-type human APP
[106] while N-methyl-D-aspartate (NMDA) receptor
hypo-sensitivity was reported in Tg APP mice ex-
pressing a synthetic (i.e. non-FAD) mutation at the
K-secretase site [86]. Once the electrophysiological
phenotype associated with expression of full-length
mutated APP has been clearly di¡erentiated from
that of wt human APP expressed at a similar level,
it will be of interest to explore the molecular events
underlying altered synaptic plasticity in mutant APP
mice.
6. Prospects
Applying the criteria that an animal ‘model’ for
AD (1) should exhibit progressive AD-like neuropa-
thology, (2) should exhibit cognitive de¢cits, (3)
should discern pathogenic e¡ects of FAD mutations
from those of APP overexpression, and (4) should be
robust, encompassing more than one Tg line and (5)
should be validated in several laboratories, it is pos-
sible to exclude all transgenic ‘models’ of AD created
to date. This conclusion is perhaps not that surpris-
ing. It is a re£ection both of (i) the complexity of
AD, a complexity underscored by no less than four
predisposing genes just for the familial form of the
disease, and (ii) the challenge of recapitulating a hu-
man disease, that may not present until the sixth or
seventh decade, in animals with a maximum lifespan
of only 3 years, and (iii) performing reproducible
behavioral studies in laboratory mice. However, by
extension, yet more pessimistic scenarios have to be
considered. One is a potential pitfall in transgenic
strategies exploiting early-onset disease programmed
by rare FAD mutations, as such models might not be
applicable to sporadic AD (though very similar neu-
ropathologies in AD and FAD would tend to coun-
ter this argument). Another is that Tg mice will never
recapitulate all facets of this human disease, due to
divergence of molecular substrates and disparate
baseline level of cognitive function. Only further
work will establish whether this ‘species elitist’ posi-
tion has any validity, or whether the fundamental
biochemical similarities between rodents and mam-
mals noted in other diseases also provide a level play-
ing ¢eld vis-a'-vis modeling of AD. Most likely the
¢nal outcome will be somewhere in between. Cer-
tainly, it is important to note that many new sub-
strates and technologies remain to be incorporated
into the paradigms discussed here. A partial list
would include strategies to maximize AL production
while minimizing lethality and spurious phenotypic
traits associated with APP overexpression (i.e. bear-
ing no clear relationship to the accepted hallmarks of
AD) [33,40], humanizing for other potential AD sub-
strates or co-factors (tau, the amyloid plaque com-
ponent K-synuclein, RAGE [107], and ERAB [108]),
use of inducible transgenes, and use of other types of
Tg animals (e.g. rats, pigs). We would venture to
suggest that incorporation of these new elements
will both highlight the inadequacy of extant models
and, more importantly, move us closer to the accu-
rate AD facsimiles that will be required for the de-
velopment of preventative and curative therapies.
7. Note added in proof
Two recent papers focusing on behavioral changes
in LAPP transgenic mice. The ¢rst describes bigenic
mice carrying the APP mutation (K670N/M671L)
and the FAD4 (M146L) presenilin 1 mutation
[109]. The bigenic Tg mice showed impairment in
Y-maze performance, which was unchanged between
6 and 9 months of age, and which was not correlated
with increased AL plaque burden in the age span
studied. Interestingly, the mice did not show any
impairment in the spatial navigation when tested at
6 and 9 months in the water maze. The authors con-
clude that AL deposits may not be su⁄cient to pre-
cipitate cognitive impairment in a complex genetic
background that includes Swiss Webster, C57BL6,
SJL, and DBA2 strains. The second paper docu-
ments behavioral changes of Tg2576 mice in a bat-
tery of tests carried out at 3 and 9 months of age
[110]. Progressive, gender-related impairment of Tg
mice was observed in some tests.
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